Sirtuin modulators: an updated patent review (2012 – 2014)

Bibliography

• Dang W. The controversial world of sirtuins. Drug Discov Today Technol 2014;12:e9-e17
   PubMedGoogle Scholar
• Du J, Zhou Y, Su X, et al. Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase. Science 2011;334:806-9
   PubMed Web of Science ®Google Scholar
• Jiang H, Khan S, Wang Y, et al. SIRT6 Regulates TNF-α Secretion through Hydrolysis of Long-Chain Fatty Acyl Lysine. Nature 2013;496:110-13
   PubMed Web of Science ®Google Scholar
• Michishita E, Park JY, Burneskis JM, et al. Evolutionarily Conserved and Nonconserved Cellular Localizations and Functions of Human SIRT Proteins. Mol Biol Cell 2005;16:4623-35
   PubMed Web of Science ®Google Scholar
• Yuan H, Su L, Chen WY. The Emerging and Diverse Roles of Sirtuins in Cancer: a Clinical Perspective. OncoTargets Ther 2013;6:1399-416
   PubMed Web of Science ®Google Scholar
• Iwahara T, Bonasio R, Narendra V, et al. SIRT3 Functions in the Nucleus in the Control of Stress-Related Gene Expression. Mol Cell Biol 2012;32:5022-34
   PubMed Web of Science ®Google Scholar
• Kincaid B, Bossy-Wetzel E. Forever Young: SIRT3 a Shield against Mitochondrial Meltdown, Aging, and Neurodegeneration. Front. Aging Neurosci 2013;5:48
   PubMed Web of Science ®Google Scholar
• Laurent G, German NJ, Saha AK, et al. SIRT4 Coordinates the Balance between Lipid Synthesis and Catabolism by Repressing Malonyl CoA Decarboxylase. Mol Cell 2013;50:686-98
   PubMed Web of Science ®Google Scholar
• Sebastián C, Zwaans BMM, Silberman DM, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 2012;151:1185-99
   PubMed Web of Science ®Google Scholar
• Song NY, Surh YJ. Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci 2012;1271:10-19
   PubMed Web of Science ®Google Scholar
• Liu T, Liu PY, Marshall GM. The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer. Cancer Res 2009;69:1702-5
   PubMed Web of Science ®Google Scholar
• Hiratsuka M, Inoue T, Toda T, et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003;309:558-66
   PubMed Web of Science ®Google Scholar
• Park SH, Zhu Y, Ozden O, et al. SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis. Transl Cancer Res 2012;1:15-21
   PubMed Web of Science ®Google Scholar
• McGlynn LM, Zino S, MacDonald AI, et al. SIRT2: tumour suppressor or tumour promoter in operable breast cancer? Eur J Cancer 2014;50:290-301
   PubMed Web of Science ®Google Scholar
• Alhazzazi TY, Kamarajan P, Verdin E, et al. Sirtuin-3 (SIRT3) and the Hallmarks of Cancer. Genes Cancer 2013;4:164-71
   PubMedGoogle Scholar
• Lyssiotis CA, Cantley LC. SIRT6 puts cancer metabolism in the driver’s seat. Cell 2012;151:1155-6
   PubMed Web of Science ®Google Scholar
• Lerrer B, Cohen HY. The Guardian: metabolic and Tumour-Suppressive Effects of SIRT6. EMBO J 2013;32:7-8
   PubMed Web of Science ®Google Scholar
• Barber MF, Michishita-Kioi E, Xi Y, et al. SIRT7 Links H3K18 Deacetylation to Maintenance of Oncogenic Transformation. Nature 2012;487:114-18
   PubMed Web of Science ®Google Scholar
• Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005;280:40364-74
   PubMed Web of Science ®Google Scholar
• Parker JA, Arango M, Abderrahmane S, et al. Resveratrol Rescues Mutant Polyglutamine Cytotoxicity in Nematode and Mammalian Neurons. Nat Genet 2005;37:349-50
   PubMed Web of Science ®Google Scholar
• Jeong H, Cohen DE, Cui L, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 2012;18:159-65
   Web of Science ®Google Scholar
• Luthi-Carter R, Taylor DM, Pallos J, et al. G. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 2010;107:7927-32
   PubMed Web of Science ®Google Scholar
• Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson’s disease. Science 2007;317:516-19
   PubMed Web of Science ®Google Scholar
• Docherty JJ, Sweet TJ, Bailey E, et al. Resveratrol inhibition of varicella-zoster virus replication in vitro. Antiviral Res 2006;72:171-7
   PubMed Web of Science ®Google Scholar
• Zhang HS, Zhou Y, Wu MR, et al. Resveratrol inhibited Tat-Induced HIV-1 LTR transactivation via NAD(+)-dependent SIRT1 activity. Life Sci 2009;85:484-9
   PubMed Web of Science ®Google Scholar
• Picchione KE, Bhattacharjee A. Viral genome silencing by neuronal sirtuin 1. J Neurovirol 2011;17:184-8
   PubMed Web of Science ®Google Scholar
• Shenk T, Koyuncu E, Cristea I. Sirtuin modulators as virus production modulators. WO2012106509; 2012
   Google Scholar
• Sauer S, Holzhauser S, Feldmann R, et al. Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents. EP2759295A1; 2014
   Google Scholar
• Philp A, Schenk S, Baar K. Method for increasing muscle growth by blocking sirtuin activity. WO2014110399A1; 2014
   Google Scholar
• Duke CC, Tran VH, Duke RK. Prenylated hydroxystilbenes. WO2012149608A1; 2012
   Google Scholar
• Blum CA, Disch JS, Evindar G, et al. Thieno[3,2-d]pyrimidine-6-carboxamides and analogues as sirtuin modulators. WO2014138562A1; 2014
   Google Scholar
• Lin H. Modulators for Sirt5 and assays for screening same. WO2012006391A2; 2012
   Google Scholar
• Lin H, Cerione R. Methods for treatment of cancer by targeting Sirt5. WO2013036720A1; 2013
   Google Scholar
• Zemel M, Grindstaff IED, Bruckbauer A. Compositions and methods for modulating metabolic pathways. US2013017283A1; 2013
   Google Scholar
• Greco SJ, Tezapsidis N. Compositions and methods for delaying senescence or cell death in neurons. US2013065825A1; 2013
   Google Scholar
• Vu CB. Quinazolinone and related analogs as sirtuin modulators. US2012165330A1; 2012
   Google Scholar
• Blum C, Springer S, Vu C. Substituted Bicyclic Aza-Heterocycles and Analogues as Sirtuin Modulators. WO2013059589A1; 2013
   Google Scholar
• Blum C, Disch J, Springer S. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators. WO2013059594A1; 2013
   Google Scholar
• Casaubon R, Narayan R, Oalmann C, et al. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators. WO2013059587A1; 2013
   Google Scholar
• Vu CB, Disch JS, Springer SK, et al. Quinolines and related analogs as sirtuin modulators. US8685970B2; 2014
   Google Scholar
• Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of sirt1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:12-716
   PubMed Web of Science ®Google Scholar
• Hubbard BP, Gomes AP, Dai H, et al. Evidence for a common mechanism of sirt1 regulation by allosteric activators. Science 2013;339:1216-19
   PubMed Web of Science ®Google Scholar
• Larsen BD, Andersen S, Larsen MS. Novel heterocyclic compounds useful in sirtuin binding and modulation. WO2013090369A1; 2013
   Google Scholar
• Dillin A, Kelly JW. Medicine. The yin-yang of sirtuins. Science 2007;317:461-2
   PubMed Web of Science ®Google Scholar
• Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010;285:8340-51
   PubMed Web of Science ®Google Scholar
• Dai H, Kustigian L, Carney D, et al. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 2010;285:32695-703
   PubMed Web of Science ®Google Scholar
• Arunachalam G, Samuel SM, Marei I, et al. Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br J Pharmacol 2014;171:523-35
   PubMed Web of Science ®Google Scholar